Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis

Gastrointestinal Endoscopy

Volumn 69, Issue 3, 2009, Pages 462-472

  Sherman, Stuart ^a   Alazmi, Waleed M ^a   Lehman, Glen A ^a   Geenen, Joseph E ^a   Chuttani, Ram ^a   Kozarek, Richard A ^a   Welch, William D ^a   Souza, Sonia ^a   Pribble, John ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMYLASE; PLACEBO; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; BLOOD SAMPLING; CANNULATION; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INCIDENCE; INFECTION; INSOMNIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MANOMETRY; NAUSEA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOMNOLENCE; TACHYCARDIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VATER PAPILLA STENOSIS; VOMITING;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE DISEASE; AGED, 80 AND OVER; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PANCREATITIS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 60349110869     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2008.07.040     Document Type: Article

References (63)

1. Cotton P.B., Lehman G., Vennes J., et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 37 (1991) 383-393
2. Freeman M.L., DiSario J.A., Nelson D.B., et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54 (2001) 425-434
3. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 335 (1996) 909-918
4. Andriulli A., Clemente R., Solmi L., et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56 (2002) 488-495
5. Boender J., Nix G.A., de Ridder M.A., et al. Endoscopic papillotomy for common bile duct stones: factors influencing the complication rate. Endoscopy 26 (1994) 209-216
6. Chen Y.K., Foliente R.L., Santoro M.J., et al. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 89 (1994) 327-333
7. Christoforidis E., Goulimaris I., Kanellos I., et al. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 34 (2002) 286-292
8. Friedland S., Soetikno R.M., Vandervoort J., et al. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 34 (2002) 483-488
9. Loperfido S., Angelini G., Benedetti G., et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 48 (1998) 1-10
10. Masci E., Toti G., Mariani A., et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 96 (2001) 417-423
11. Mehta S.N., Pavone E., Barkun J.S., et al. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. Endoscopy 30 (1998) 457-463
12. Rabenstein T., Schneider H.T., Bulling D., et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 32 (2000) 10-19
13. Sherman S., Ruffolo T.A., Hawes R.H., et al. Complications of endoscopic sphincterotomy: a prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 101 (1991) 1068-1075
14. Tzovaras G., Shukla P., Kow L., et al. What are the risks of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography?. Aust N Z J Surg 70 (2000) 778-782
15. Vandervoort J., Soetikno R.M., Tham T.C., et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 56 (2002) 652-656
16. Christensen M., Matzen P., Schulze S., et al. Complications of ERCP: a prospective study. Gastrointest Endosc 60 (2004) 721-731
17. Freeman M.L., and Guda N.M. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59 (2004) 845-864
18. Hogan W.J. Stenting the pancreas: is this the solution to post-ERCP pancreatitis?. Gastroenterology 115 (1998) 1591-1594
19. Tarnasky P.R., Palesh Y.Y., Cunningham J.T., et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 115 (1998) 1518-1524
20. Smithline A., Silverman W., Rogers D., et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 39 (1993) 652-657
21. Fazel A., Quadri A., Catalano M.F., et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 57 (2003) 291-294
22. Aizawa T., and Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 54 (2001) 209-213
23. Sherman S., Bucksot E.L., Esber E., et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-induced pancreatitis? Randomized prospective study. [abstract]. Am J Gastroenterol 90 (1995) 241
24. Sherman S., Hawes R.H., Rathgaber S.W., et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 40 (1994) 422-427
25. Johnson G.K., Geenen J.E., Bedford R.A., et al. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Gastrointest Endosc 42 (1995) 312-316
26. Sherman S., Blaut U., Watkins J.L., et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 58 (2003) 23-29
27. Poon R.T., Yeung C., Lo C.M., et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 49 (1999) 593-598
28. Andriulli A., Solmi L., Loperfido S., et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2 (2004) 713-718
29. Cavallini G., Tittobello A., Frulloni L., et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography: gabexate in digestive endoscopy: Italian Group. N Engl J Med 335 (1996) 919-923
30. Binmoeller K.F., Harris A.G., Dumas R., et al. Does the somatostatin analogue octreotide protect against ERCP-induced pancreatitis?. Gut 33 (1992) 1129-1133
31. Sternlieb J.A., Aronchick C.A., Retig J.N., et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 87 (1992) 1561-1566
32. Arcidiacono R., Gambitta P., Rossi A., et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 26 (1994) 715-718
33. Testoni P.A., Lella F., Bagnolo F., et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas 13 (1996) 61-65
34. Dumont J.A., Conwell D.L., Zuccaro G., et al. A randomized double blind study of interleukin 10 for prevention of ERCP-induced pancreatitis. Am J Gastroenterol 96 (2001) 2098-2102
35. Moreto M., Zaballa M., Cassado I., et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial. Gastrointest Endosc 57 (2003) 1-7
36. Rabenstein T., Roggenbuck Framke B., Martus P., et al. Complication of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?. Gastrointest Endosc 55 (2002) 476-483
37. Raty S., Sand J., Pulkkinen M., et al. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 5 (2001) 339-345
38. Deviere J., Le Moine O., Van Laethem J.L., et al. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 120 (2001) 498-505
39. Sudhindran S., Bromwich E., and Edwards P.R. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 88 (2001) 1178-1182
40. Murray B., Carter R., Imrie C., et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124 (2003) 1786-1791
41. Poon R.T., Yeung C., Liu C.L., et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut 52 (2003) 1768-1773
42. Masci E., Cavallini G., Mariani A., et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 98 (2003) 2182-2186
43. Jowell P.S., Branch S., Robuck-Mangum G., et al. Synthetic secretin administered at the start of the procedure significantly reduces the risk of post-ERCP pancreatitis: a randomized, double-blind, placebo controlled trial. [abstract]. Gastroenterology 125 (2003) 605
44. Arvanitidis D., Anagnostopoulos G.K., Giannopoulos D., et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 19 (2004) 278-282
45. Gorelick A., Barnett J., Chey W., et al. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 36 (2004) 170-173
46. Prat F., Amaris J., Ducot B., et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 56 (2002) 202-208
47. Schwartz J.J., Lew R.J., Ahmad N.A., et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 179-184
48. Budzynska A., Marek T., Nowak A., et al. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33 (2001) 766-772
49. Jaworek J., and Konturek S.J. Effects of prostaglandin of E, F and I series, leukotriene C and platelet activating factor on amylase release from isolated rat pancreatic acini. J Physiol Pharmacol 44 (1993) 365-381
50. Emanuelli G., Montrucchio G., Dughera L., et al. Role of platelet activating factor in acute pancreatitis induced by lipopolysaccharides in rabbits. Eur J Pharmacol 261 (1994) 265-272
51. Alonso R., Montero A., Arevalo M., et al. Platelet-activating factor mediates pancreatic function derangement in caerulein-induced pancreatitis in rats. Clin Sci 87 (1994) 85-90
52. Zhou W., McCollum M.O., Levine B.A., et al. Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat. Am J Pathol 140 (1992) 971-979
53. Fujimura K., Kubota Y., Ogura M., et al. Role of endogenous platelet-activating factor in caerulein-induced acute pancreatitis in rats: protective effects of a PAF-antagonist. J Gastroenterol Hepatol 7 (1992) 199-202
54. Konturek S.J., Dembinski A., Konturek P.J., et al. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 33 (1992) 1268-1274
55. Tomaszewska R., Dembinski A., Warzecha Z., et al. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis: a morphologic and functional study in the rat. J Physiol Pharmacol 43 (1992) 345-352
56. Hofbauer B., Saluja A.K., Bhatia M., et al. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 115 (1998) 1238-1247
57. Formela L.J., Wood L.M., Whittaker M., et al. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 81 (1994) 1783-1785
58. Sandoval D., Gukovskaya A., Reavey P., et al. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 111 (1996) 1081-1091
59. Summers J.B., and Albert D.H. Platelet activating factor antagonists. Adv Pharmacol 32 (1995) 67-168
60. Bedirli A., Gokahmetoglu S., Sakrak O., et al. Beneficial effects of recombinant platelet-activating factor acetylhydrolase and BN 52021 on bacterial translocation in cerulein-induced pancreatitis. Eur Surg Res 36 (2004) 136-141
61. Kingsnorth A.N. Early treatment with lexipafant, a platelet activating factor antagonist reduces mortality in acute pancreatitis: a double blind, randomized, placebo controlled study. [abstract]. Gastroenterology 112 (1997) A453
62. Kingsnorth A.N., Galloway S.W., and Formela L.J. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 82 (1995) 1414-1420
63. Johnson C.D., Kingsnorth A.N., Imrie C.W., et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 48 (2001) 62-69